KR101693675B1 - 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 - Google Patents

페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 Download PDF

Info

Publication number
KR101693675B1
KR101693675B1 KR1020150178339A KR20150178339A KR101693675B1 KR 101693675 B1 KR101693675 B1 KR 101693675B1 KR 1020150178339 A KR1020150178339 A KR 1020150178339A KR 20150178339 A KR20150178339 A KR 20150178339A KR 101693675 B1 KR101693675 B1 KR 101693675B1
Authority
KR
South Korea
Prior art keywords
less
pemetrexed
months
colorless
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020150178339A
Other languages
English (en)
Korean (ko)
Inventor
주민재
서혜진
박신정
Original Assignee
주식회사 종근당
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020150178339A priority Critical patent/KR101693675B1/ko
Application filed by 주식회사 종근당 filed Critical 주식회사 종근당
Priority to JP2018550317A priority patent/JP2019502751A/ja
Priority to CN201680073091.9A priority patent/CN108463251A/zh
Priority to EP16876001.5A priority patent/EP3391908A4/en
Priority to MYPI2018702294A priority patent/MY191043A/en
Priority to US16/061,450 priority patent/US10792285B2/en
Priority to PCT/KR2016/014594 priority patent/WO2017105059A1/ko
Priority to HK18114448.9A priority patent/HK1255313A1/zh
Application granted granted Critical
Publication of KR101693675B1 publication Critical patent/KR101693675B1/ko
Priority to PH12018501274A priority patent/PH12018501274A1/en
Priority to JP2020091920A priority patent/JP2020125359A/ja
Priority to JP2022088229A priority patent/JP2022107687A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020150178339A 2015-12-14 2015-12-14 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 Active KR101693675B1 (ko)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020150178339A KR101693675B1 (ko) 2015-12-14 2015-12-14 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
HK18114448.9A HK1255313A1 (zh) 2015-12-14 2016-12-13 含有培美曲塞或其药学上可接受的盐的稳定药物组合物
EP16876001.5A EP3391908A4 (en) 2015-12-14 2016-12-13 STABILIZED PHARMACEUTICAL COMPOSITION WITH PEMETREXED OR PHARMACEUTICAL ACCEPTABLE SALT
MYPI2018702294A MY191043A (en) 2015-12-14 2016-12-13 Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
US16/061,450 US10792285B2 (en) 2015-12-14 2016-12-13 Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
PCT/KR2016/014594 WO2017105059A1 (ko) 2015-12-14 2016-12-13 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP2018550317A JP2019502751A (ja) 2015-12-14 2016-12-13 ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
CN201680073091.9A CN108463251A (zh) 2015-12-14 2016-12-13 含有培美曲塞或其药学上可接受的盐的稳定药物组合物
PH12018501274A PH12018501274A1 (en) 2015-12-14 2018-06-14 Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
JP2020091920A JP2020125359A (ja) 2015-12-14 2020-05-27 ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
JP2022088229A JP2022107687A (ja) 2015-12-14 2022-05-31 ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150178339A KR101693675B1 (ko) 2015-12-14 2015-12-14 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물

Publications (1)

Publication Number Publication Date
KR101693675B1 true KR101693675B1 (ko) 2017-01-06

Family

ID=57832487

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150178339A Active KR101693675B1 (ko) 2015-12-14 2015-12-14 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물

Country Status (9)

Country Link
US (1) US10792285B2 (https=)
EP (1) EP3391908A4 (https=)
JP (3) JP2019502751A (https=)
KR (1) KR101693675B1 (https=)
CN (1) CN108463251A (https=)
HK (1) HK1255313A1 (https=)
MY (1) MY191043A (https=)
PH (1) PH12018501274A1 (https=)
WO (1) WO2017105059A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019244965A1 (ja) * 2018-06-20 2020-06-25 日本化薬株式会社 ペメトレキセドナトリウム注射用溶液製剤、並びにその製造方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN117693334B (zh) * 2022-06-09 2025-11-18 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用
JP2024006619A (ja) 2022-07-04 2024-01-17 セイコーエプソン株式会社 印刷装置、情報処理装置、情報処理システム、処理方法、及び、プログラム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020081293A (ko) * 2000-02-04 2002-10-26 일라이 릴리 앤드 캄파니 페메트렉시드를 모노티오글리세롤 ｌ-시스테인 또는티오글리콜산과 함께 포함하는 제약 조성물
JP2013540104A (ja) * 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
KR20140132621A (ko) * 2013-05-08 2014-11-18 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
KR20150020266A (ko) * 2012-05-31 2015-02-25 스타다 알쯔나이미텔 아게 약제학적 페메트렉시드 액제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
KR20130122065A (ko) 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (en) * 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
EP2854768B2 (en) * 2012-05-30 2025-06-18 Fresenius Kabi Oncology Limited Pharmaceutical compositions of pemetrexed
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
EP3040074B1 (en) * 2013-10-03 2018-07-25 Fujifilm Corporation Injection preparation and method for producing same
JP6099557B2 (ja) * 2013-12-27 2017-03-22 富士フイルム株式会社 注射液製剤及びその製造方法
KR101574875B1 (ko) * 2014-02-13 2015-12-04 건양대학교산학협력단 안정화된 페니실린 복합 현탁 제제
ES2686870T3 (es) * 2014-03-28 2018-10-22 Fujifilm Corporation Preparación de inyección y método para producirla
WO2016151365A1 (en) * 2015-03-26 2016-09-29 Ftf Pharma Private Limited Pharmaceutical composition of pemetrexed
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020081293A (ko) * 2000-02-04 2002-10-26 일라이 릴리 앤드 캄파니 페메트렉시드를 모노티오글리세롤 ｌ-시스테인 또는티오글리콜산과 함께 포함하는 제약 조성물
JP2013540104A (ja) * 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
KR20150020266A (ko) * 2012-05-31 2015-02-25 스타다 알쯔나이미텔 아게 약제학적 페메트렉시드 액제
KR20140132621A (ko) * 2013-05-08 2014-11-18 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019244965A1 (ja) * 2018-06-20 2020-06-25 日本化薬株式会社 ペメトレキセドナトリウム注射用溶液製剤、並びにその製造方法

Also Published As

Publication number Publication date
PH12018501274A1 (en) 2019-02-04
JP2020125359A (ja) 2020-08-20
HK1255313A1 (zh) 2019-08-16
MY191043A (en) 2022-05-30
EP3391908A1 (en) 2018-10-24
WO2017105059A1 (ko) 2017-06-22
US10792285B2 (en) 2020-10-06
CN108463251A (zh) 2018-08-28
JP2022107687A (ja) 2022-07-22
JP2019502751A (ja) 2019-01-31
US20200261458A1 (en) 2020-08-20
EP3391908A4 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
KR101485243B1 (ko) 안정화된 페메트렉시드 제제
KR101260636B1 (ko) 안정화된 페메트렉시드 제제
CN102018714B (zh) 制剂
JP2022107687A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
EP2991619B1 (en) Stable pharmaceutical composition containing folates
CN105611932A (zh) 注射液制剂及其制造方法
KR20130122065A (ko) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2991618B1 (en) Stable high strength pharmaceutical composition of levoleucovorin
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
US20100249413A1 (en) Stabilized pharmaceutical composition
CN101500571A (zh) 稳定的冻干制剂
KR20200052326A (ko) 코판리십의 제제
CN114096267B (zh) 特利加压素制剂
US20160235717A1 (en) Bendamustine pharmaceutical compositions
JP2019502751A5 (https=)
US20200246263A1 (en) Stable liquid compositions of pemetrexed
KR101487953B1 (ko) 유기용매 무함유 젬시타빈 수용액 조성물
US20230226051A1 (en) Trabectedin composition
KR20250153621A (ko) 안정성이 개선된 페메트렉시드를 포함하는 약제학적 제제
NZ581791A (en) Stable formulations of thiadiazole derivative
EP3222271A1 (en) Stable pharmaceutical composition comprising pemetrexed or pharmaceutically acceptable salt thereof
HK1212224B (en) A stabilized pemetrexed formulation
JP2008297277A (ja) 注射剤の安定化法

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20191223

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10